Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
Phase 2
Terminated
- Conditions
- Stroke
- Interventions
- Drug: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)Drug: Saline Placebo
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2011-11-29
- Lead Sponsor
- Stem Cell Therapeutics Corp.
- Target Recruit Count
- 96
- Registration Number
- NCT00938314
- Locations
- 🇮🇳
Care Hospital, Hyderabad, Andhra Pradesh, India
🇮🇳St.Theresa's General Hospital, Hyderabad, Andhra Pradesh, India
🇨🇦Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada
REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTxâ„¢-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
Phase 2
Withdrawn
- Conditions
- Stroke
- Interventions
- Drug: Saline Placebo
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2011-09-05
- Lead Sponsor
- Stem Cell Therapeutics Corp.
- Target Recruit Count
- 30
- Registration Number
- NCT00715364
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸University of California, Irvine Medical Center, Orange, California, United States
REGENESIS (CA): A Study of NTxâ„¢-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
Phase 2
Terminated
- Conditions
- Stroke
- Interventions
- Drug: Saline placebo
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2009-08-12
- Lead Sponsor
- Stem Cell Therapeutics Corp.
- Target Recruit Count
- 134
- Registration Number
- NCT00663416
- Locations
- 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
🇮🇳M S Ramaiah Memorial Hospital, Bangalore, Karnataka, India
🇨🇦Walter Mackenzie Health Sciences Centre, Edmonton, Alberta, Canada
© Copyright 2025. All Rights Reserved by MedPath